Dronedarone HClAntiarrhythmic drugs CAS# 141625-93-6 |
- MK-4827
Catalog No.:BCC1761
CAS No.:1038915-60-4
- BMN-673 8R,9S
Catalog No.:BCC1422
CAS No.:1207456-00-5
- XAV-939
Catalog No.:BCC1120
CAS No.:284028-89-3
- PJ34
Catalog No.:BCC1865
CAS No.:344458-19-1
- ABT-888 (Veliparib)
Catalog No.:BCC1267
CAS No.:912444-00-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 141625-93-6 | SDF | Download SDF |
| PubChem ID | 219025 | Appearance | Powder |
| Formula | C31H45ClN2O5S | M.Wt | 593.22 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 50 mg/mL (84.29 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide;hydrochloride | ||
| SMILES | CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl | ||
| Standard InChIKey | DWKVCQXJYURSIQ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C31H44N2O5S.ClH/c1-5-8-12-29-30(27-23-25(32-39(4,35)36)15-18-28(27)38-29)31(34)24-13-16-26(17-14-24)37-22-11-21-33(19-9-6-2)20-10-7-3;/h13-18,23,32H,5-12,19-22H2,1-4H3;1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Dronedarone hydrochloride is a non-iodinated amiodarone derivative that inhibits Na+, K+ and Ca2+ currents.In Vitro:Dronedarone (SR-33589) is a multichannel blocker for atrial fibrillation . It is a potent inhibitor of the acetylcholine-activated K+ current from atrial and sinoatrial nodal tissue, and inhibits the rapid delayed rectifier more potently than slow and inward rectifier K+ currents and inhibits L-type calcium current. Under whole-cell patch clamp, it blocks IKr (IC50=3 μM) and ICa-L (IC50=0.18 μM). The effects on ICa-L are use- and frequency-dependent. Dronedarone inhibits current carried by human ether-a-go-go gene (HERG)-expressing oocytes (analagous to IKr) with an IC50 of 9 μM[1]. In guinea pig ventricular myocytes, dronedarone exhibits a state dependent inhibition of the fast Na+ channel current with an IC50 of 0.7±0.1 μM, when the holding potential is −80 mV[2].In Vivo:Dronedarone (Hydrochloride) reduces significantly the incidence of ventricular fibrillation (VF) from 80 to 30% (p < 0.05) at 3 mg/kg i.v. and eliminated VF and mortality at 10 mg/kg i.v. [3]. Dronedarone inhibited carotid artery thrombus formation in vivo. Thrombin- and collagen-induced platelet aggregation is impaired indronedarone-treated mice (P .05), and expression ofplasminogen activator inhibitor-1 (PAI1), an inhibitor of the fibrinolytic system, is reduced in the arterial wall[4]. References: | |||||
Dronedarone HCl Dilution Calculator
Dronedarone HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.6857 mL | 8.4286 mL | 16.8572 mL | 33.7143 mL | 42.1429 mL |
| 5 mM | 0.3371 mL | 1.6857 mL | 3.3714 mL | 6.7429 mL | 8.4286 mL |
| 10 mM | 0.1686 mL | 0.8429 mL | 1.6857 mL | 3.3714 mL | 4.2143 mL |
| 50 mM | 0.0337 mL | 0.1686 mL | 0.3371 mL | 0.6743 mL | 0.8429 mL |
| 100 mM | 0.0169 mL | 0.0843 mL | 0.1686 mL | 0.3371 mL | 0.4214 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Dronedarone HCL is an amiodarone analogue which has been shown an effective and promising treatment for Atrial fibrillation (AF) [1].
In vitro, dronedarone has been demonstrated to inhibit muscarinic acetylcholine receptor-operated K+ current IK(ACh) induced by carbachol or GTP-gamma-S with IC50 values of 10nm and <100nm, respectively, in cells isolated from guinea pig atria. Notably, dronedarone was 100-fold potent and selective over amiodarone in inhibiting IK(ACh) [1].
In vivo, dronedarone has shown to block arterial thrombus formation, decrease platelet aggregation and reduce plasminogen activator inhibitor-1 (PAI1) expression in C57Bl/6 mice [2].
References:
[1] Guillemare E1, Marion A, Nisato D, Gautier P. Inhibitory effects of dronedarone on muscarinic K+ current in guinea pig atrial cells. J Cardiovasc Pharmacol. 2000 Dec;36(6):802-5.
[2] Breitenstein A1, Sluka SH, Akhmedov A, Stivala S, Steffel J, Camici GG, Riem HH, Beer HJ, Studt JD, Duru F, Luscher TF, Tanner FC. Dronedarone reduces arterial thrombus formation. Basic Res Cardiol. 2012 Nov;107(6):302.
- Beta-D-glucopyranosyl oleanolate
Catalog No.:BCN6530
CAS No.:14162-53-9
- JW 642
Catalog No.:BCC6324
CAS No.:1416133-89-5
- UNC1215
Catalog No.:BCC2023
CAS No.:1415800-43-9
- Angustin B
Catalog No.:BCN7652
CAS No.:1415795-51-5
- Angustin A
Catalog No.:BCN7651
CAS No.:1415795-50-4
- ST-836 hydrochloride
Catalog No.:BCC1969
CAS No.:1415564-68-9
- PF-543 Citrate
Catalog No.:BCC1855
CAS No.:1415562-83-2
- PF-543
Catalog No.:BCC1854
CAS No.:1415562-82-1
- Crizotinib hydrochloride
Catalog No.:BCC5306
CAS No.:1415560-69-8
- GSK256066 2,2,2-trifluoroacetic acid
Catalog No.:BCC1605
CAS No.:1415560-64-3
- CDK9 inhibitor
Catalog No.:BCC1465
CAS No.:1415559-43-1
- MK-8245 Trifluoroacetate
Catalog No.:BCC1769
CAS No.:1415559-41-9
- (±)-BI-D
Catalog No.:BCC5537
CAS No.:1416258-16-6
- Dronedarone
Catalog No.:BCN2176
CAS No.:141626-36-0
- CU CPT 22
Catalog No.:BCC6320
CAS No.:1416324-85-0
- GR 94800
Catalog No.:BCC5799
CAS No.:141636-65-9
- Ivangustin
Catalog No.:BCN3507
CAS No.:14164-59-1
- Thrombin Receptor Activator for Peptide 5 (TRAP-5)
Catalog No.:BCC1025
CAS No.:141685-53-2
- NPEC-caged-D-AP5
Catalog No.:BCC7895
CAS No.:1416943-27-5
- Galanin (2-29) (rat)
Catalog No.:BCC5763
CAS No.:141696-11-9
- Faropenem daloxate
Catalog No.:BCC1571
CAS No.:141702-36-5
- RI-2
Catalog No.:BCC6424
CAS No.:1417162-36-7
- H-Phe(4-Cl)-OH
Catalog No.:BCC3171
CAS No.:14173-39-8
- H-DL-Phe(4-Cl)-OMe.HCl
Catalog No.:BCC3175
CAS No.:14173-40-1
Identification and characterization of stress degradation products of dronedarone hydrochloride employing LC-UV/PDA, LC-MS/TOF and MS(n) studies.[Pubmed:26547261]
J Pharm Biomed Anal. 2016 Jan 25;118:139-148.
Dronedarone HCl was subjected to forced decomposition conditions of hydrolysis (neutral, acidic and alkaline), oxidation, photolysis and thermal stress, as suggested in the ICH guideline Q1A(R2). The drug showed significant degradation under alkaline hydrolytic and alkaline photolytic conditions while it remained stable in neutral, acidic, thermal and oxidative conditions. In total, six degradation products (I-VI) were formed, which could be separated by chromatography on C18 (250 mm x 4.6 mm; 5 mu, Xterra) column using isocratic elution method. Detection wavelength was selected as 288 nm. Multi-stage (MS(n)) and MS/TOF accurate mass studies were carried out to establish the complete fragmentation pathway of the drug which in turn was utilized in characterization of the products. The degradation pathway of the drug leading to generation of products I-VI was postulated and this has not been reported so far.
